IFN-α2 Antibody (9D3): sc-57222
- IFN-α2 Antibody (9D3) is a mouse monoclonal IgG1 provided at 100 µg/ml
- raised against full length IFN-α2b of human origin
- recommended for detection of recombinant IFN-α2a and IFN-α2b of human origin by WB and ELISA; non cross-reactive with IFN-α5 or IFN-γ
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for IFN-α2 Antibody (9D3). This work is in progress.
IFN-α2 Antibody (9D3) is a mouse monoclonal IgG1 antibody that detects IFN-α2 in human samples through applications such as western blotting (WB) and enzyme-linked immunosorbent assay (ELISA). IFN-α2, a member of the type I interferon family, plays a crucial role in the immune response by inducing antiviral activity and modulating the immune system. This cytokine is primarily produced by leukocytes in response to viral infections and is essential for the activation of immune cells, including natural killer cells and macrophages, which are vital for controlling viral replication and tumor growth. The importance of IFN-α2 extends to therapeutic applications, as IFN-α2 is increasingly utilized in clinical settings to treat various malignancies, myelodysplastic syndromes, and autoimmune diseases. Additionally, IFN-α2 interacts with the type I interferon receptor, which is a multisubunit receptor that also binds other interferons, thereby amplifying the immune response. The ability of IFN-α2 to modulate immune pathways makes IFN-α2 a significant target for research and therapeutic interventions, highlighting the relevance of anti-IFN-α2 antibody (9D3) in advancing our understanding of immune regulation and treatment strategies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
IFN-α2 Antibody (9D3) References:
- Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2. | Robinson, SP., et al. 1990. Breast Cancer Res Treat. 15: 95-101. PMID: 2138919
- Characterization of three monoclonal antibodies that recognize the interferon alpha 2 receptor. | Colamonici, OR., et al. 1990. Proc Natl Acad Sci U S A. 87: 7230-4. PMID: 2144902
- Transient Increase of Pre-existing Anti-IFN-α2 Antibodies Induced by SARS-CoV-2 Infection. | Steels, S., et al. 2022. J Clin Immunol. 42: 742-745. PMID: 35296990
- Effects of recombinant interferon-alpha 2 treatment upon lipid concentrations and lipoprotein composition. | Massaro, ER., et al. 1986. J Interferon Res. 6: 655-62. PMID: 3572087
- Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinoma. | Kempf, RA., et al. 1986. J Biol Response Mod. 5: 27-35. PMID: 3958753
- Immunological effects of recombinant interferon-alpha 2 in cancer patients. | Hengst, JC., et al. 1983. J Biol Response Mod. 2: 516-27. PMID: 6663321
- Peptide-mapping of three neutralizing epitopes into predicted biologically active sites of human interferon-alpha 2. | Kontsek, P., et al. 1993. Immunol Lett. 35: 281-4. PMID: 7685736
- Interferon-alpha 2 counteracts interleukin-1 alpha-stimulated expression of urokinase-type plasminogen activator in human foreskin microvascular endothelial cells in vitro. | Wojta, J., et al. 1994. Lymphokine Cytokine Res. 13: 133-8. PMID: 8061114
- Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2. | Atzpodien, J., et al. 1993. Tumour Biol. 14: 354-9. PMID: 8265981
- Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2. | Egle, A., et al. 1996. Eur J Immunol. 26: 3119-26. PMID: 8977313
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IFN-α2 Antibody (9D3) | sc-57222 | 100 µg/ml | $322.00 |